Share

    


Home / Search Results

Search Results

You searched for:

Dr. Barbara Schmidtman highlights key findings from the 2022 ACCC Mini Z burnout survey, comparing results from the pre-pandemic 2019 to now.
In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
Put yourself first: this mantra is especially important today as we continue to grapple with the implications and fallout from the COVID-19 global pandemic.
As we turn the corner toward 2022, for oncology to drive equity forward: We need every member and every discipline, patient, leader, payer, industry partner, and innovator working together to provide the most equitable care possible in a sustainable way.